AR056204A1 - Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas - Google Patents
Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadasInfo
- Publication number
- AR056204A1 AR056204A1 ARP060104275A ARP060104275A AR056204A1 AR 056204 A1 AR056204 A1 AR 056204A1 AR P060104275 A ARP060104275 A AR P060104275A AR P060104275 A ARP060104275 A AR P060104275A AR 056204 A1 AR056204 A1 AR 056204A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- hydroxyl
- group
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Estos compuestos y las composiciones farmacéuticas que los contienen, son utiles para el tratamiento de la obesidad, hiperfagia, la ansiedad, la depresion y trastornos y enfermedades afines. Reivindicacion 1: Un compuesto de la formula (1), en la que R1 es bencimidazol o azabencimidazol, sin substituir o mono-, bi- o tri-substituido por un resto elegido entre el grupo formado por halogeno, hidroxilo, -SCH3, -SO2CH3, fenilo, cicloalquilo C3-6, oxígeno, alcoxi C1-6, alcoílo C1-6, alquilo C1-6, halogeno-alquilo C1-6 y alquilo C1-6 substituido por hidroxilo; R2 se elige entre el grupo formado por hidrogeno, halogeno, alquilo C1-6, hidroxilo, halogeno-alquilo C1-6, alquilo C1-6 substituido por hidroxilo, -OCH2C(CH3)2OH, -SCH3, -OSO2CH3, alcoxi C1-6, -CH2OH y -CH2OCH3; A es C-R3 o N; uno de R3 o R4 es hidrogeno o halogeno y el otro se elige entre el grupo formado por hidrogeno, halogeno, alquilo C1-6, -CN, -NH2, -NHCH3, -NHCO-R5, -OCH3 y azaindano; R5 se elige entre el grupo formado por alquilo C1-6, halogeno-alquilo C1-6, alquilo C1-6 substituido por hidroxilo, alcoxi C1-6, cicloalquilo C3-6, un heterociclo que es un anillo heteroaromático de 5 o 6 eslabones, unido mediante un átomo de carbono de un anillo que tiene 1 a 3 heteroátomos en el anillo, elegidos entre el grupo formado por S, N y O, y alquilo C1-6 substituido por un anillo heteroaromático de 5 o 6 eslabones que está unido mediante un átomo de carbono de un anillo que tiene 1 a 3 heteroátomos en el anillo, elegidos entre el grupo formado por S, N y O; Ra y Rb, son hidrogeno o bien Ra y Rb, están reemplazados por un enlace -C-C- con el fin de formar un doble enlace entre los átomos de carbono a los que están unidos Ra y Rb; y sales farmacéuticamente aceptables del mismo. Reivindicacion 17: Un compuesto de la formula (2), en la que R1 es bencimidazol o azabencimidazol, sin substituir o mono-, bi- o tri-substituido por un resto elegido entre el grupo formado por halogeno, hidroxilo, -SCH3, fenilo, cicloalquilo C3-6, oxígeno, alcoxi C1-6, alquilo C1-6 ramificado o sin ramificar y alquilo C1-6 ramificado o sin ramificar substituido por hidroxilo; R2 es hidrogeno, halogeno, alquilo C1-6 substituido o sin substituir, hidroxilo, - OCH2C(CH3)OH, -SCH3, -OSO2CH3, alcoxi C1-6, -CH2OH o -CH2OCH3; R3 es H o halogeno; R4 es hidrogeno, halogeno, alquilo C1-6, -CN, -NH2, -NHCH3, -NHCO-R5, -OCH3 o azaindano; R5 es alquilo C1-6 substituido o sin substituir, ramificado o sin ramificar, alcoxi C1-6, cicloalquilo C3-6, o un heterociclo que es un anillo de 5 o 6 eslabones unido mediante un átomo de carbono de un anillo que tiene 1 a 3 heteroátomos en el anillo, elegidos entre el grupo formado por S, N y O; y sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72261005P | 2005-09-30 | 2005-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056204A1 true AR056204A1 (es) | 2007-09-26 |
Family
ID=37813513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104275A AR056204A1 (es) | 2005-09-30 | 2006-09-28 | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7803816B2 (es) |
| EP (1) | EP1934199B1 (es) |
| JP (1) | JP4870163B2 (es) |
| KR (1) | KR101020333B1 (es) |
| CN (1) | CN101273026A (es) |
| AR (1) | AR056204A1 (es) |
| AT (1) | ATE429428T1 (es) |
| AU (1) | AU2006298852A1 (es) |
| BR (1) | BRPI0616646A2 (es) |
| CA (1) | CA2623722A1 (es) |
| DE (1) | DE602006006463D1 (es) |
| ES (1) | ES2322965T3 (es) |
| IL (1) | IL190152A (es) |
| TW (1) | TW200800943A (es) |
| WO (1) | WO2007039462A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US7652053B2 (en) * | 2006-11-30 | 2010-01-26 | Hoffmann-La Roche Inc. | Diaminocycloalkane MCH receptor antagonists |
| WO2009155527A2 (en) * | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| JP2010090110A (ja) * | 2008-09-12 | 2010-04-22 | Sumitomo Chemical Co Ltd | Ｎ−置換−トランス−４−アジドピペリジン−３−オールの製造方法 |
| JP2010209058A (ja) | 2008-09-29 | 2010-09-24 | Sumitomo Chemical Co Ltd | １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| UY32442A (es) * | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| ES2758677T3 (es) * | 2015-01-20 | 2020-05-06 | Olon Spa | Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis |
| KR101719321B1 (ko) * | 2016-03-31 | 2017-03-23 | 충남대학교산학협력단 | 3-(4-클로로페닐)벤조[4, 5]이미다조[2, 1-b]싸이아졸-6-카복실산을 포함하는 항비만 또는 항우울증 치료용 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998054168A1 (fr) * | 1997-05-30 | 1998-12-03 | Banyu Pharmaceutical Co., Ltd. | Derives de 2-0xoimidazole |
| US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| AU7315700A (en) | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| CA2431953A1 (en) | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
| SI1598339T1 (sl) * | 2001-04-18 | 2009-12-31 | Euro Celtique Sa | Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine |
| WO2002089729A2 (en) | 2001-05-04 | 2002-11-14 | Tularik Inc. | Fused heterocyclic compounds |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| RU2323935C2 (ru) * | 2002-04-18 | 2008-05-10 | Шеринг Корпорейшн | Производные бензимидазола, их применение и фармацевтическая композиция на их основе, обладающая свойствами антагониста рецептора гистамина h3 |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2004092181A1 (en) | 2003-04-11 | 2004-10-28 | Smithkline Beecham Corporation | Heterocyclic mchr1 antagonists |
| AU2004266228A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonists |
| JP2007502287A (ja) | 2003-08-13 | 2007-02-08 | アムジェン インコーポレイテッド | メラニン凝集ホルモン受容体アンタゴニスト |
| US20050040257A1 (en) | 2003-08-19 | 2005-02-24 | Seitz David M. | Atomizer with dedicated cleaning fluid system |
| TWI290140B (en) * | 2003-08-25 | 2007-11-21 | Schering Corp | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders |
| MXPA06003738A (es) | 2003-10-02 | 2006-06-14 | Schering Corp | Aminobenzimidazoles como antagonistas selectivos del receptor de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. |
| AR045843A1 (es) * | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
| WO2005042541A1 (en) | 2003-10-23 | 2005-05-12 | Glaxo Group Limited | 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety |
| US20050137243A1 (en) | 2003-12-23 | 2005-06-23 | Souers Andrew J. | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
-
2006
- 2006-09-20 CN CNA2006800354917A patent/CN101273026A/zh active Pending
- 2006-09-20 KR KR1020087010206A patent/KR101020333B1/ko not_active IP Right Cessation
- 2006-09-20 BR BRPI0616646-6A patent/BRPI0616646A2/pt not_active IP Right Cessation
- 2006-09-20 AT AT06793670T patent/ATE429428T1/de active
- 2006-09-20 ES ES06793670T patent/ES2322965T3/es active Active
- 2006-09-20 WO PCT/EP2006/066540 patent/WO2007039462A2/en active Application Filing
- 2006-09-20 DE DE602006006463T patent/DE602006006463D1/de active Active
- 2006-09-20 JP JP2008532728A patent/JP4870163B2/ja not_active Expired - Fee Related
- 2006-09-20 EP EP06793670A patent/EP1934199B1/en not_active Not-in-force
- 2006-09-20 CA CA002623722A patent/CA2623722A1/en not_active Abandoned
- 2006-09-20 AU AU2006298852A patent/AU2006298852A1/en not_active Abandoned
- 2006-09-25 US US11/526,523 patent/US7803816B2/en not_active Expired - Fee Related
- 2006-09-27 TW TW095135862A patent/TW200800943A/zh unknown
- 2006-09-28 AR ARP060104275A patent/AR056204A1/es not_active Application Discontinuation
-
2008
- 2008-03-13 IL IL190152A patent/IL190152A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007039462A3 (en) | 2007-06-21 |
| JP2009510012A (ja) | 2009-03-12 |
| DE602006006463D1 (de) | 2009-06-04 |
| US20070078165A1 (en) | 2007-04-05 |
| IL190152A (en) | 2012-09-24 |
| US7803816B2 (en) | 2010-09-28 |
| ATE429428T1 (de) | 2009-05-15 |
| JP4870163B2 (ja) | 2012-02-08 |
| CN101273026A (zh) | 2008-09-24 |
| CA2623722A1 (en) | 2007-04-12 |
| TW200800943A (en) | 2008-01-01 |
| EP1934199B1 (en) | 2009-04-22 |
| IL190152A0 (en) | 2008-08-07 |
| KR101020333B1 (ko) | 2011-03-09 |
| KR20080059264A (ko) | 2008-06-26 |
| ES2322965T3 (es) | 2009-07-02 |
| BRPI0616646A2 (pt) | 2011-06-28 |
| EP1934199A2 (en) | 2008-06-25 |
| WO2007039462A2 (en) | 2007-04-12 |
| AU2006298852A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| ECSP066829A (es) | 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| PE20060689A1 (es) | Derivados de sulfonamidas como antagonistas de receptores orexina 2 | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR082968A1 (es) | Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto | |
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |